This bill aims to significantly strengthen the United States' domestic capacity for producing essential medical materials by amending the Defense Production Act of 1950 (DPA). It explicitly includes medical materials, such as drugs, devices, and biological products, as critical for national defense, mandating that DPA authorities be utilized to ensure their availability while considering U.S. competitiveness, scientific leadership, and innovative capacity. A key provision requires the President, in consultation with several cabinet secretaries, to transmit a comprehensive strategy to Congress within 180 days. This strategy must detail a plan to use DPA authorities to secure medical material supply chains, analyze vulnerabilities, and recommend measures for diversification. It also requires a discussion of potential impacts on production and cost, a timeline to prevent exclusive foreign government control of essential components, and efforts to mitigate risks to U.S. scientific leadership and competitiveness. Furthermore, the bill authorizes the President to make payments to eligible U.S.-organized entities to increase the security of supply chains and supply chain activities. These entities must produce critical components, critical technology, or raw materials vital for national defense. The President must certify to Congress that such payments are critical before they are made, and is also required to define "supply chain" and "supply chain activities" through regulation to guide these investments.